AbobotulinumtoxinA using 2-mL dilution (500 U/2-mL) maintains durable improvement across multiple treatment cycles

Area of Science:

• Neurology
• Movement Disorders
• Botulinum Toxin Therapy

Background:

• Cervical dystonia (CD) is a chronic neurological disorder causing involuntary neck muscle contractions and abnormal postures.
• AbobotulinumtoxinA (aboBoNT-A) offers flexible dosing with 2-mL dilutions (250 U/mL) for individualized patient care.
• This study evaluated the long-term safety and efficacy of repeat aboBoNT-A treatments in adults with CD.

Purpose of the Study:

• To assess the long-term safety and efficacy of repeated abobotulinumtoxinA (aboBoNT-A) treatments.
• To evaluate the use of a 2-mL dilution for flexible dosing in cervical dystonia patients.
• To determine the risk-benefit profile of extended aboBoNT-A therapy.

Main Methods:

• An open-label extension study involving 112 patients with cervical dystonia.
• Patients received up to three additional aboBoNT-A treatments every 12-16 weeks.
• Safety assessed via treatment-emergent adverse events (TEAEs); efficacy measured by Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) scores.

Main Results:

• Treatment-emergent adverse events (TEAEs) were reported by 22.8-35.7% of patients across treatment cycles.
• The most frequent TEAEs included dysphagia, muscular weakness, and neck pain (10.7% each).
• Mean TWSTRS total scores improved from 37.7 at baseline to 30.1 at week 12 of the third cycle.

Conclusions:

• Extended treatment with abobotulinumtoxinA (aboBoNT-A) using a 2-mL dilution is effective for cervical dystonia.
• The therapy demonstrates a favorable risk-benefit profile for long-term management.
• Repeat treatments contribute to sustained symptom improvement in CD patients.